The impact of antibiotic management on resistance

Pharmacotherapy

Volumn 24, Issue 12 II, 2004, Pages

  Bosso, John A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antibiotic management; Antibiotic restriction; Formulary restriction; Formulary substitution; Resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; CITROBACTER; CONFERENCE PAPER; DRUG APPROVAL; DRUG CONTROL; DRUG FORMULARY; DRUG INDICATION; DRUG SENSITIVITY; DRUG USE; ENTEROBACTER; ENTEROBACTERIACEAE; HUMAN; INFECTION; INFECTION CONTROL; NONHUMAN;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DISEASE MANAGEMENT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 9644302442     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.18.224S.52233     Document Type: Conference Paper

References (19)

1. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-8.
2. Neuhauser MM, Weinstein RA, Rydman R, Danzinger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone dose. JAMA 2003;289:885-8.
3. Mutnik AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
4. Bhavnani SM, Callen WA, Forrest A, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health-Syst Pharm 2003;60:1962-70.
5. Chiew YF, Yeo SF, Hall LM, Livermore DM. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. J Antimicrob Chemother 1998;41:247-51.
6. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46:2920-5.
7. Friedrich LV, White RL, Bosso JA. Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Clin Infect Dis 1999;28:1017-24.
8. Mebis J, Goossens H, Bruyneel P, et al. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 1998;12:1627-9.
9. Geffroy CE, Gray C, Stamatoullas A, Fruchart C, Tilly H. Cefepime decreases the resistance of inducible Enterobacteriaceae. Presented at the 5th international symposium of febrile neutropenia, Brussels, Belgium, December 10-13, 1997.
10. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991;35:1284-90.
11. King JW, White MC, Todd JR, Conrad SA. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992;14:908-15.
12. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020-5.
13. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999;28:1062-6.
14. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-7.
15. Lautenbach E, LaRosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003;36:440-6.
16. Regal RE, DePestel DD, VandenBussche HL. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital. Pharmacotherapy 2003;23:618-24.
17. Smith DW. Decreased antimicrobial resistance following changes in antibiotic use. Surg Infect 2000;1:73-8.
18. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003;37:180-6.
19. Empey KM, Rapp RP, Evans ME. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 2002;22:81-7.